# Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer

> **NCT00003243** · PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins**

## Conditions studied

- Leukemia
- Lymphoma
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Diseases

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** therapeutic allogeneic lymphocytes
- **DRUG:** cyclophosphamide
- **DRUG:** etoposide
- **DRUG:** pegylated liposomal doxorubicin hydrochloride

## Key facts

- **NCT ID:** NCT00003243
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-01
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2010-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003243, "Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00003243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*